Prognostic nutritional index, but not NLR or PLR, is linked to survival in multiple myeloma
By
Nermin Keni Begendi
Mustafa Duran
Yaşar Culha
May 28, 2026
Clinical Scorecard: Association of Prognostic Nutritional Index with Survival Outcomes in Newly Diagnosed Multiple Myeloma, Unlike NLR and PLR
At a Glance
Category Detail
Condition Key Mechanisms Prognostic Nutritional Index (PNI), Neutrophil-Lymphocyte Ratio (NLR), Platelet-Lymphocyte Ratio (PLR) Target Population Care Setting
Key Highlights
Low PNI (≤34.7) associated with higher mortality (76.3% vs. 50%) Median overall survival shorter in low PNI group (13.5 months vs. 53.3 months) NLR and PLR did not show significant prognostic value High beta-2 microglobulin levels linked to increased risk of death (3.19-fold) Study included 97 patients with a median follow-up of 22.3 months Guideline-Based Recommendations
Diagnosis
Diagnosis of MM based on clinical presentation, laboratory findings, bone marrow examination, and imaging studies according to IMWG criteria Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients diagnosed with Multiple Myeloma aged ≥18 years
Clinical Best Practices
Calculate PNI using serum albumin and total lymphocyte count Assess NLR and PLR but note their limited prognostic value in MM Consider beta-2 microglobulin levels in risk assessment Related Resources & Content
